Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/poly-adp-ribose-inhibition-exploring-a-new-approach-to-breast-cancer-V1JEg1QLL8
References (55)
-
P. Fong, D. Boss, T. Yap, A. Tutt, P. Wu, M. Mergui-Roelvink, Peter Mortimer, H. Swaisland, A. Lau, M. O’Connor, A. Ashworth, J. Carmichael, S. Kaye, J. Schellens, J. Bono (2009)
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.The New England journal of medicine, 361 2
-
J. Madalinska, J. Hollenstein, E. Bleiker, M. Beurden, H. Valdimarsdottir, L. Massuger, K. Gaarenstroom, M. Mourits, R. Verheijen, E. Dorst, H. Putten, K. Velden, H. Boonstra, N. Aaronson (2005)
Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 28
-
M. King, S. Wieand, Kathryn Hale, Ming Lee, T. Walsh, K. Owens, J. Tait, L. Ford, B. Dunn, J. Costantino, L. Wickerham, N. Wolmark, B. Fisher (2001)
Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.JAMA, 286 18
-
S. Isakoff, B. Overmoyer, N. Tung, R. Gelman, V. Giranda, K. Bernhard, K. Habin, L. Ellisen, E. Winer, P. Goss (2010)
A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer.Journal of Clinical Oncology, 28
-
A. Eisen, J. Lubiński, J. Klijn, P. Møller, H. Lynch, K. Offit, B. Weber, T. Rebbeck, S. Neuhausen, P. Ghadirian, W. Foulkes, R. Gershoni-baruch, E. Friedman, G. Rennert, T. Wagner, C. Isaacs, C. Kim-sing, P. Ainsworth, P. Sun, S. Narod (2005)
Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 30
-
T. Rebbeck, T. Friebel, H. Lynch, S. Neuhausen, L. Veer, J. Garber, G. Evans, S. Narod, C. Isaacs, E. Matloff, M. Daly, O. Olopade, B. Weber (2004)
Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 6
-
T. Rebbeck, H. Lynch, S. Neuhausen, S. Narod, L. Veer, J. Garber, G. Evans, C. Isaacs, M. Daly, E. Matloff, O. Olopade, B. Weber (2002)
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.The New England journal of medicine, 346 21
-
L. Rutqvist, B. Cedermark, U. Glas, A. Mattsson, L. Skoog, A. Somell, T. Theve, N. Wilking, J. Askergren, M. Hjalmar, S. Rotstein, L. Perbeck, U. Ringborg (1991)
Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy.Journal of the National Cancer Institute, 83 18
-
B. Evers, R. Drost, Eva Schut, M. Bruin, Eline Burg, P. Derksen, H. Holstege, Xiaoling Liu, E. Drunen, H. Beverloo, G. Smith, N. Martin, A. Lau, M. O’Connor, J. Jonkers (2008)
Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and CisplatinClinical Cancer Research, 14
-
T. Rebbeck, N. Kauff, S. Domchek (2009)
Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation CarriersJNCI Journal of the National Cancer Institute, 101
-
P. Fong, T. Yap, D. Boss, C. Carden, M. Mergui-Roelvink, C. Gourley, J. Grève, J. Lubiński, S. Shanley, C. Messiou, R. A’Hern, A. Tutt, A. Ashworth, J. Stone, J. Carmichael, J. Schellens, J. Bono, S. Kaye (2010)
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 15
-
V. Vogel, V. Vogel, J. Costantino, D. Wickerham, W. Cronin, R. Cecchini, J. Atkins, T. Bevers, L. Fehrenbacher, E. Pajon, J. Wade, A. Robidoux, R. Margolese, J. James, C. Runowicz, P. Ganz, S. Reis, W. McCaskill-Stevens, L. Ford, V. Jordan, N. Wolmark (2010)
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast CancerCancer Prevention Research, 3
-
A. Rijnsburger, M. Essink‐bot, S. Dooren, G. Borsboom, C. Seynaeve, C. Bartels, J. Klijn, A. Tibben, A. Tibben, H. Koning (2004)
Impact of screening for breast cancer in high-risk women on health-related quality of lifeBritish Journal of Cancer, 91
-
B. Fisher, J. Costantino, C. Redmond, R. Poisson, D. Bowman, J. Couture, N. Dimitrov, N. Wolmark, D. Wickerham, Edwin Fisher, R. Margolese, A. Robidoux, H. Shibata, J. Terz, A. Paterson, M. Feldman, W. Farrar, James Evans, H. Lickley, Mary Ketner (1989)
A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.The New England journal of medicine, 320 8
-
H. Bryant, N. Schultz, H. Thomas, Kayan Parker, Dan Flower, Elena Lopez, S. Kyle, M. Meuth, N. Curtin, T. Helleday (2005)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymeraseNature, 434
-
L. Hartmann, D. Schaid, J. Woods, T. Crotty, J. Myers, P. Arnold, P. Petty, T. Sellers, Joanne Johnson, S. McDonnell, M. Frost, Robert Jenkins (1999)
Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer.The New England journal of medicine, 340 2
-
E. Warner, K. Hill, P. Causer, D. Plewes, R. Jong, M. Yaffe, W. Foulkes, P. Ghadirian, H. Lynch, F. Couch, J. Wong, F. Wright, P. Sun, S. Narod (2011)
Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 13
-
N. Turner, J. Reis-Filho, J. Reis-Filho, AM Russell, R. Springall, K. Ryder, D. Steele, K. Savage, C. Gillett, F. Schmitt, A. Ashworth, A. Tutt, A. Tutt (2007)
BRCA1 dysfunction in sporadic basal-like breast cancerOncogene, 26
-
S. Kopetz, M. Overman, D. Chang, K. Glover, I. Shureiqi, R. Wolff, J. Abbruzzese, C. Eng (2008)
Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 12
-
Y. Drew, E. Mulligan, Wan-Tse Vong, H. Thomas, Samra Kahn, S. Kyle, A. Mukhopadhyay, G. Los, Z. Hostomský, E. Plummer, R. Edmondson, N. Curtin (2011)
Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.Journal of the National Cancer Institute, 103 4
-
B. Fisher, J. Costantino, D. Wickerham, C. Redmond, M. Kavanah, W. Cronin, V. Vogel, A. Robidoux, N. Dimitrov, J. Atkins, M. Daly, S. Wieand, E. Tan-chiu, L. Ford, N. Wolmark (1999)
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.Journal of the National Cancer Institute, 90 18
-
M. Beattie, B. Crawford, F. Lin, E. Vittinghoff, J. Ziegler (2009)
Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers.Genetic testing and molecular biomarkers, 13 1
-
T. Hay, H. Jenkins, O. Sansom, N. Martin, G. Smith, A. Clarke (2005)
Efficient deletion of normal Brca2-deficient intestinal epithelium by poly(ADP-ribose) polymerase inhibition models potential prophylactic therapy.Cancer research, 65 22
-
H. Meijers-Heijboer, B. Geel, W. Putten, S. Henzen‐Logmans, C. Seynaeve, M. Menke-Pluymers, C. Bartels, L. Verhoog, A. Ouweland, M. Niermeijer, C. Brekelmans, J. Klijn (2001)
Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.The New England journal of medicine, 345 3
-
Karen Johnson, P. Brown (2010)
Drug development for cancer chemoprevention: focus on molecular targets.Seminars in oncology, 37 4
-
V. Vogel, J. Costantino, D. Wickerham, W. Cronin, R. Cecchini, J. Atkins, T. Bevers, L. Fehrenbacher, E. Pajon, J. Wade, A. Robidoux, R. Margolese, J. James, S. Lippman, C. Runowicz, P. Ganz, S. Reis, W. McCaskill-Stevens, L. Ford, V. Jordan, N. Wolmark (2006)
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.JAMA, 295 23
-
Sining Chen, G. Parmigiani (2007)
Meta-analysis of BRCA1 and BRCA2 penetrance.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 11
-
K. Metcalfe, H. Lynch, P. Ghadirian, N. Tung, I. Olivotto, E. Warner, O. Olopade, A. Eisen, B. Weber, Jane McLennan, P. Sun, W. Foulkes, S. Narod (2004)
Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 12
-
J. O’Shaughnessy, C. Osborne, J. Pippen, M. Yoffe, D. Patt, C. Rocha, I. Koo, B. Sherman, C. Bradley (2011)
Iniparib plus chemotherapy in metastatic triple-negative breast cancer.The New England journal of medicine, 364 3
-
A. Skytte, A. Gerdes, M. Andersen, Lone Sunde, K. Brøndum‐Nielsen, M. Waldstrøm, S. Kolvraa, D. Crüger (2010)
Risk‐reducing mastectomy and salpingo‐oophorectomy in unaffected BRCA mutation carriers: uptake and timing *Clinical Genetics, 77
-
E. Gartner, A. Burger, P. LoRusso (2010)
Poly(ADP-Ribose) Polymerase Inhibitors: A Novel Drug Class With a Promising FutureThe Cancer Journal, 16
-
K. Gelmon (2011)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialBreast Diseases: A Year Book Quarterly, 22
-
D. Saslow, C. Boetes, W. Burke, S. Harms, M. Leach, C. Lehman, E. Morris, E. Pisano, M. Schnall, S. Sener, Robert Smith, E. Warner, M. Yaffe, Kimberly Andrews, C. Russell (2007)
American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to MammographyCA: A Cancer Journal for Clinicians, 57
-
L. Carey, N. Sharpless (2011)
PARP and cancer--if it's broke, don't fix it.The New England journal of medicine, 364 3
-
J. Mahany, N. Lewis, E. Heath, P. LoRusso, M. Mita, J. Rodón, A. Tolcher, B. Sherman, C. Bradley, K. Papadopoulos (2008)
A phase IB study evaluating BSI-201 in combination with chemotherapy in subjects with advanced solid tumorsJournal of Clinical Oncology, 26
-
S. Rottenberg, J. Jaspers, A. Kersbergen, Eline Burg, A. Nygren, Serge Zander, P. Derksen, M. Bruin, J. Zevenhoven, A. Lau, R. Boulter, A. Cranston, M. O’Connor, N. Martin, P. Borst, J. Jonkers (2008)
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugsProceedings of the National Academy of Sciences, 105
-
W. Rubinstein (2007)
Hereditary breast cancer: pathobiology, clinical translation, and potential for targeted cancer therapeuticsFamilial Cancer, 7
-
H. Farmer, N. Mccabe, C. Lord, A. Tutt, Damian Johnson, T. Richardson, M. Santarosa, Krystyna Dillon, I. Hickson, C. Knights, N. Martin, S. Jackson, G. Smith, A. Ashworth (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 434
-
B. Heemskerk-Gerritsen, C. Brekelmans, M. Menke-Pluymers, A. Geel, M. Tilanus-Linthorst, C. Bartels, M. Tan, H. Meijers-Heijboer, J. Klijn, C. Seynaeve (2007)
Prophylactic Mastectomy in BRCA1/2 Mutation Carriers and Women at Risk of Hereditary Breast Cancer: Long-Term Experiences at the Rotterdam Family Cancer ClinicAnnals of Surgical Oncology, 14
-
D. Atchley, C. Albarracin, Adriana López, V. Valero, Chris Amos, A. González-Angulo, G. Hortobagyi, B. Arun (2008)
Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 26
-
J. Soto, C. Deng (2006)
PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers?International Journal of Medical Sciences, 3
-
M. Audeh, J. Carmichael, R. Penson, M. Friedlander, B. Powell, K. Bell-McGuinn, C. Scott, J. Weitzel, A. Oaknin, N. Loman, K. Lu, R. Schmutzler, U. Matulonis, M. Wickens, A. Tutt (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trialThe Lancet, 376
-
S. Kummar, R. Kinders, M. Gutierrez, L. Rubinstein, R. Parchment, L. Phillips, J. Ji, A. Monks, J. Low, A. Chen, A. Murgo, J. Collins, S. Steinberg, H. Eliopoulos, V. Giranda, G. Gordon, L. Helman, R. Wiltrout, J. Tomaszewski, J. Doroshow (2009)
Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 16
-
K. Metcalfe, D. Birenbaum-Carmeli, J. Lubiński, J. Gronwald, H. Lynch, P. Møller, P. Ghadirian, W. Foulkes, J. Klijn, E. Friedman, C. Kim-sing, P. Ainsworth, B. Rosen, S. Domchek, T. Wagner, N. Tung, S. Manoukian, F. Couch, P. Sun, S. Narod (2008)
International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriersInternational Journal of Cancer, 122
-
S. Domchek, T. Friebel, C. Singer, D. Evans, H. Lynch, C. Isaacs, J. Garber, S. Neuhausen, E. Matloff, R. Eeles, G. Pichert, Laura t'veer, N. Tung, J. Weitzel, F. Couch, W. Rubinstein, P. Ganz, M. Daly, O. Olopade, G. Tomlinson, J. Schildkraut, J. Blum, T. Rebbeck (2010)
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.JAMA, 304 9
-
N. Kauff, J. Satagopan, M. Robson, Lauren Scheuer, M. Hensley, C. Hudis, N. Ellis, J. Boyd, P. Borgen, R. Barakat, L. Norton, M. Castiel, K. Nafa, K. Offit (2002)
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.The New England journal of medicine, 346 21
-
J. Iglehart, D. Silver (2009)
Synthetic lethality--a new direction in cancer-drug development.The New England journal of medicine, 361 2
-
N. Kauff, S. Domchek, T. Friebel, M. Robson, Johanna Lee, J. Garber, C. Isaacs, D. Evans, H. Lynch, R. Eeles, S. Neuhausen, M. Daly, E. Matloff, J. Blum, P. Sabbatini, R. Barakat, C. Hudis, L. Norton, K. Offit, T. Rebbeck (2008)
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 8
-
B. Fisher, J. Costantino, D. Wickerham, R. Cecchini, W. Cronin, A. Robidoux, T. Bevers, M. Kavanah, J. Atkins, R. Margolese, C. Runowicz, J. James, L. Ford, N. Wolmark, N. Wolmark (2005)
Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.Journal of the National Cancer Institute, 97 22
-
S. Kopetz, M. Mita, Isabel Mok, K. Sankhala, Jennifer Moseley, B. Sherman, C. Bradley, A. Tolcher (2008)
First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumorsJournal of Clinical Oncology, 26
-
GaryJ. Kelloff, Scott, M. Lippman, AndrewJ. Dannenberg, C. Sigman, H. Pearce, BrianJ. Reid, E. Szabo, M. Spitz, Gordon B.Mills, V. Papadimitrakopoulou, R. Lotan, B. Aggarwal, R. Bresalier, Jeri Kim, B. Arun, K. Lu, Melanie E.Thomas, Helen Rhodes, MollyA. Brewer, M. Follen, DongM. Shin, H. Parnes, Jill, M. Siegfried, Alison, A. Evans, W. Blot, W. Chow, Patricia, L. Blount, C. Maley, Kenneth K.Wang, S. Lam, J. Lee, StevenM. Dubinett, P. Engstrom, F. Meyskens, J. O’Shaughnessy, W. Nelson, andWaun Hong (2006)
Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer—A Plan to Move ForwardClinical Cancer Research, 12
-
TR Rebbeck, ND Kauff, SM Domchek (2009)
Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriersJ Natl Cancer Inst, 101
-
A. Tan, D. Gibbon, M. Stein, R. Moss, V. Karantza, Hongxia Lin, M. Gounder, A. Chen, M. Egorin, R. DiPaola (2010)
Preliminary results of a phase I trial of ABT-888, a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with cyclophosphamide.Journal of Clinical Oncology, 28
-
M. Schwartz, Elizabeth Kaufman, B. Peshkin, C. Isaacs, Chanita Hughes, T. Demarco, C. Finch, C. Lerman (2003)
Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 21
-
D. Evans, F. Lalloo, L. Ashcroft, A. Shenton, T. Clancy, A. Baildam, A. Brain, P. Hopwood, A. Howell (2009)
Uptake of Risk-Reducing Surgery in Unaffected Women at High Risk of Breast and Ovarian Cancer Is Risk, Age, and Time DependentCancer Epidemiology, Biomarkers & Prevention, 18
- Publisher
- Springer Journals
- Copyright
- Copyright © 2011 by Springer Science+Business Media, LLC
- Subject
- Medicine & Public Health; Internal Medicine; Oncology; Surgical Oncology
- ISSN
- 1943-4588
- eISSN
- 1943-4596
- DOI
- 10.1007/s12609-011-0049-1
- Publisher site
- See Article on Publisher Site
Abstract
Carriers of deleterious BRCA1 and BRCA2 mutations face an elevated risk of developing breast cancer. This risk warrants consideration of prevention interventions. Currently, the only proven prevention intervention for BRCA mutation carriers is risk-reducing surgery. Inhibitors of poly(ADP-ribose) polymerase (PARP) are a new class of drugs that appear to be effective in treating BRCA mutation–associated cancers and triple-negative breast cancers. PARP inhibitors may offer a new approach to breast cancer prevention in BRCA mutation carriers. This article reviews current breast cancer prevention interventions for BRCA mutation carriers and discusses the rationale for investigating new chemoprevention agents in this population. The mechanism of action of PARP inhibitors and the rationale for studying them in BRCA mutation carriers is reviewed. Published clinical trials regarding PARP inhibitors and ongoing research regarding PARP inhibitors and breast cancer prevention are reviewed.
Journal
Current Breast Cancer Reports – Springer Journals
Published: Jul 1, 2011